Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

Cancer Biol Ther. 2018 Nov 7:1-9. doi: 10.1080/15384047.2018.1523095. [Epub ahead of print]

PMID:
30403909
2.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P.

J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

3.

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one.

Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P.

Cancer Treat Rev. 2018 Nov;70:41-46. doi: 10.1016/j.ctrv.2018.07.016. Epub 2018 Jul 26. Review.

4.

Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival.

Roberto M, Botticelli A, Strigari L, Ghidini M, Onesti CE, Ratti M, Benzoni I, Pizzo C, Falcone R, Lomiento D, Donida BM, Totaro L, Mazzuca F, Marchetti P.

Med Oncol. 2018 Jun 19;35(7):111. doi: 10.1007/s12032-018-1166-8.

PMID:
29923032
5.

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.

Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, Botticelli A, Begini P, Strigari L, Marchetti P, Muscaritoli M.

Oncotarget. 2018 May 22;9(39):25714-25722. doi: 10.18632/oncotarget.25394. eCollection 2018 May 22.

6.

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.

Salati M, Baldessari C, Cerbelli B, Botticelli A.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14. No abstract available.

7.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.

PMID:
29700053
8.

Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.

Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A, Onesti CE, Lauro S, Raffa S, Torrisi MR, Marchetti P.

Anal Cell Pathol (Amst). 2018 Feb 27;2018:3506874. doi: 10.1155/2018/3506874. eCollection 2018.

9.

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Cerbelli B, Pernazza A, Botticelli A, Fortunato L, Monti M, Sciattella P, Campagna D, Mazzuca F, Mauri M, Naso G, Marchetti P, d'Amati G, Costarelli L.

Biomed Res Int. 2017;2017:1750925. doi: 10.1155/2017/1750925. Epub 2017 Dec 14.

10.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P.

Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16.

PMID:
29336662
11.

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.

Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, Osti MF, Marchetti P.

Medicine (Baltimore). 2017 Dec;96(48):e9023. doi: 10.1097/MD.0000000000009023.

12.

Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong.

Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, Lauro S.

J Thorac Dis. 2017 Nov;9(11):E985-E989. doi: 10.21037/jtd.2017.09.74.

13.

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P.

Oncotarget. 2017 Nov 1;8(59):99336-99346. doi: 10.18632/oncotarget.22242. eCollection 2017 Nov 21.

14.

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

15.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.

Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P.

Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.

16.

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.

Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.

J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27.

PMID:
28710865
17.

Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.

Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F.

HPB (Oxford). 2017 Sep;19(9):741-748. doi: 10.1016/j.hpb.2017.05.010. Epub 2017 Jul 3. Review.

18.

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

Sini V, Botticelli A, Lunardi G, Gori S, Marchetti P.

Pharmacogenomics. 2017 Jun;18(8):821-830. doi: 10.2217/pgs-2017-0006. Epub 2017 Jun 8. Review.

PMID:
28592202
19.

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, DI Pietro FR, Rossi A, Simmaco M, Mazzuca F, Marchetti P.

Anticancer Res. 2017 May;37(5):2633-2639.

PMID:
28476838
20.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.

Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492.

PMID:
28296649
21.

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P.

Eur J Clin Pharmacol. 2017 Feb;73(2):157-164. doi: 10.1007/s00228-016-2160-8. Epub 2016 Nov 18.

PMID:
27864592
22.

5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.

Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Mar;28(3):322-326. doi: 10.1097/CAD.0000000000000453.

PMID:
27845948
23.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P.

Oncotarget. 2017 Jan 31;8(5):8890-8899. doi: 10.18632/oncotarget.12985. Review.

24.

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2017 Feb 21;8(8):14050-14057. doi: 10.18632/oncotarget.12571.

25.

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B, Romiti A, Occhipinti M, Sebastiani C, Lionetto L, Marchetti L, Simmaco M, Marchetti P, Mazzuca F.

PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105. eCollection 2016.

26.

The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

Romiti A, Roberto M, D'Antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P.

Anticancer Drugs. 2016 Nov;27(10):1044-9. doi: 10.1097/CAD.0000000000000429.

PMID:
27557140
27.

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Mazzuca F, Botticelli A, Mazzotti E, La Torre M, Borro M, Marchetti L, Maddalena C, Gentile G, Simmaco M, Marchetti P.

Eurasian J Med. 2016 Feb;48(1):10-4. doi: 10.5152/eurasianjmed.2015.008. Epub 2015 Jul 7.

28.

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.

Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2016 Apr 12;7(15):20612-20. doi: 10.18632/oncotarget.7991.

29.

Positive impact of elastography in breast cancer diagnosis: an institutional experience.

Botticelli A, Mazzotti E, Di Stefano D, Petrocelli V, Mazzuca F, La Torre M, Ciabatta FR, Giovagnoli RM, Marchetti P, Bonifacino A.

J Ultrasound. 2015 Aug 12;18(4):321-7. doi: 10.1007/s40477-015-0177-y. eCollection 2015 Dec.

30.

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

Botticelli A, Mazzuca F, Borro M, Mazzotti E, La Torre M, Bonifacino A, Ciabatta FR, Gentile G, Maddalena C, Simmaco M, Marchetti P.

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

31.

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy.

Mazzuca F, Borro M, Botticelli A, Aimati L, Gentile G, Capalbo C, Maddalena C, Mazzotti E, Simmaco M, Marchetti P.

World J Oncol. 2015 Aug;6(4):394-397. doi: 10.14740/wjon930w. Epub 2015 Aug 27.

32.

Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.

Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M.

Pharmacogenomics J. 2016 Aug;16(4):320-5. doi: 10.1038/tpj.2015.56. Epub 2015 Jul 28.

PMID:
26216193
33.

Electrochemotherapy treatment of cutaneous metastases from breast cancer.

Mercantini P, Lorenzon L, Tarantino G, Balducci G, Ferri M, Mazzuca F, Botticelli A, Marchetti P.

Am Surg. 2015 May;81(5):E222-5. No abstract available.

PMID:
25975317
34.

Standard versus limited colon resection for high risk T1 colon cancer. A matched case-control study.

La Torre M, Nigri G, Mazzuca F, Ferri M, Botticelli A, Lorenzon L, Pilozzi E, Ziparo V.

J Gastrointestin Liver Dis. 2014 Sep;23(3):285-90. doi: 10.15403/jgld.2014.1121.233.mlt.

35.

Breast metastasis from clear cell renal cell carcinoma.

Botticelli A, De Francesco GP, Di Stefano D.

J Ultrasound. 2013 Jul 5;16(3):127-30. doi: 10.1007/s40477-013-0026-9. eCollection 2013 Jul 5.

36.

Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways.

Giuliani D, Bitto A, Galantucci M, Zaffe D, Ottani A, Irrera N, Neri L, Cavallini GM, Altavilla D, Botticelli AR, Squadrito F, Guarini S.

Neurobiol Aging. 2014 Mar;35(3):537-47. doi: 10.1016/j.neurobiolaging.2013.08.030. Epub 2013 Oct 1.

PMID:
24094579
37.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.

38.

The importance of lymph node retrieval and lymph node ratio following preoperative chemoradiation of rectal cancer.

La Torre M, Mazzuca F, Ferri M, Mari FS, Botticelli A, Pilozzi E, Lorenzon L, Osti MF, Marchetti P, Enrici RM, Ziparo V.

Colorectal Dis. 2013 Jul;15(7):e382-8. doi: 10.1111/codi.12242.

PMID:
23581854
39.

Treatment of cerebral ischemia with melanocortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery.

Giuliani D, Zaffe D, Ottani A, Spaccapelo L, Galantucci M, Minutoli L, Bitto A, Irrera N, Contri M, Altavilla D, Botticelli AR, Squadrito F, Guarini S.

Acta Neuropathol. 2011 Oct;122(4):443-53. doi: 10.1007/s00401-011-0873-4. Epub 2011 Sep 17.

PMID:
21927944
40.

Cytopathological and chemico-physical analyses of smears of mucosa surrounding oral piercing.

Lupi SM, Zaffe D, Rodriguez y Baena R, Rizzo S, Botticelli AR.

Oral Dis. 2010 Mar;16(2):160-6. doi: 10.1111/j.1601-0825.2009.01613.x.

PMID:
20374503
41.

The effect of a triclosan dentifrice on mucositis in subjects with dental implants: a six-month clinical study.

Ramberg P, Lindhe J, Botticelli D, Botticelli A.

J Clin Dent. 2009;20(3):103-7.

PMID:
19711612
42.

Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268.

Giuliani D, Ottani A, Minutoli L, Stefano VD, Galantucci M, Bitto A, Zaffe D, Altavilla D, Botticelli AR, Squadrito F, Guarini S.

Brain Behav Immun. 2009 Aug;23(6):844-50. doi: 10.1016/j.bbi.2009.03.009. Epub 2009 Apr 5.

PMID:
19345727
43.

Vagus nerve mediates the protective effects of melanocortins against cerebral and systemic damage after ischemic stroke.

Ottani A, Giuliani D, Mioni C, Galantucci M, Minutoli L, Bitto A, Altavilla D, Zaffe D, Botticelli AR, Squadrito F, Guarini S.

J Cereb Blood Flow Metab. 2009 Mar;29(3):512-23. doi: 10.1038/jcbfm.2008.140. Epub 2008 Nov 19.

PMID:
19018269
44.

Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins.

Giuliani D, Ottani A, Mioni C, Bazzani C, Galantucci M, Minutoli L, Bitto A, Zaffe D, Botticelli AR, Squadrito F, Guarini S.

Eur J Pharmacol. 2007 Sep 10;570(1-3):57-65. Epub 2007 Jun 5.

PMID:
17588564
45.

Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage.

Giuliani D, Mioni C, Bazzani C, Zaffe D, Botticelli AR, Capolongo S, Sabba A, Galantucci M, Iannone A, Grieco P, Novellino E, Colombo G, Tomasi A, Catania A, Guarini S.

Br J Pharmacol. 2007 Mar;150(5):595-603. Epub 2007 Jan 22.

46.

Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils.

Giuliani D, Leone S, Mioni C, Bazzani C, Zaffe D, Botticelli AR, Altavilla D, Galantucci M, Minutoli L, Bitto A, Squadrito F, Guarini S.

Eur J Pharmacol. 2006 May 24;538(1-3):48-56. Epub 2006 Mar 24.

PMID:
16647700
47.

Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats.

Mioni C, Bazzani C, Giuliani D, Altavilla D, Leone S, Ferrari A, Minutoli L, Bitto A, Marini H, Zaffe D, Botticelli AR, Iannone A, Tomasi A, Bigiani A, Bertolini A, Squadrito F, Guarini S.

Crit Care Med. 2005 Nov;33(11):2621-8.

PMID:
16276189
48.

Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia.

Giuliani D, Mioni C, Altavilla D, Leone S, Bazzani C, Minutoli L, Bitto A, Cainazzo MM, Marini H, Zaffe D, Botticelli AR, Pizzala R, Savio M, Necchi D, Schiöth HB, Bertolini A, Squadrito F, Guarini S.

Endocrinology. 2006 Mar;147(3):1126-35. Epub 2005 Oct 27.

PMID:
16254026
49.

Histological study on sinus lift grafting by Fisiograft and Bio-Oss.

Zaffe D, Leghissa GC, Pradelli J, Botticelli AR.

J Mater Sci Mater Med. 2005 Sep;16(9):789-93.

PMID:
16167106
50.

Morphological, histochemical, and immunocytochemical study of CO2 and Er:YAG laser effect on oral soft tissues.

Zaffe D, Vitale MC, Martignone A, Scarpelli F, Botticelli AR.

Photomed Laser Surg. 2004 Jun;22(3):185-9.

PMID:
15315724

Supplemental Content

Loading ...
Support Center